BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its price objective increased by investment analysts at HC Wainwright from $53.00 to $56.00 in a report issued on Monday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's price objective would suggest a potential upside of 45.00% from the company's previous close.
BBIO has been the topic of several other research reports. Scotiabank upped their target price on shares of BridgeBio Pharma from $52.00 to $55.00 and gave the company a "sector outperform" rating in a research note on Wednesday, April 30th. UBS Group raised their target price on shares of BridgeBio Pharma from $65.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, April 30th. Redburn Atlantic initiated coverage on BridgeBio Pharma in a research note on Monday, March 31st. They issued a "buy" rating and a $50.00 price objective for the company. Piper Sandler lifted their price target on shares of BridgeBio Pharma from $46.00 to $63.00 and gave the company an "overweight" rating in a report on Wednesday, April 30th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $95.00 price objective on shares of BridgeBio Pharma in a research note on Friday, February 21st. Two investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $57.36.
View Our Latest Stock Report on BBIO
BridgeBio Pharma Price Performance
NASDAQ:BBIO opened at $38.62 on Monday. The firm has a market capitalization of $7.33 billion, a P/E ratio of -13.55 and a beta of 1.10. BridgeBio Pharma has a one year low of $21.62 and a one year high of $39.67. The company's 50-day simple moving average is $34.55 and its 200 day simple moving average is $32.71.
BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to analysts' expectations of $57.14 million. BridgeBio Pharma's revenue for the quarter was down 44.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.20) EPS. On average, equities research analysts expect that BridgeBio Pharma will post -3.67 earnings per share for the current fiscal year.
Insider Buying and Selling
In other BridgeBio Pharma news, major shareholder Genetic Disorder L.P. Kkr sold 6,000,000 shares of the company's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $34.20, for a total transaction of $205,200,000.00. Following the completion of the sale, the insider now owns 13,260,971 shares in the company, valued at $453,525,208.20. This represents a 31.15% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Neil Kumar sold 75,000 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was sold at an average price of $33.40, for a total value of $2,505,000.00. Following the sale, the chief executive officer now owns 4,798,447 shares of the company's stock, valued at $160,268,129.80. This trade represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 6,392,182 shares of company stock valued at $219,161,291. Company insiders own 18.20% of the company's stock.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of BBIO. Farallon Capital Management LLC boosted its stake in BridgeBio Pharma by 140.1% in the 4th quarter. Farallon Capital Management LLC now owns 4,195,000 shares of the company's stock worth $115,111,000 after purchasing an additional 2,448,000 shares in the last quarter. Driehaus Capital Management LLC purchased a new position in shares of BridgeBio Pharma in the first quarter worth $51,874,000. Invesco Ltd. lifted its stake in shares of BridgeBio Pharma by 147.0% during the first quarter. Invesco Ltd. now owns 2,206,163 shares of the company's stock worth $76,267,000 after buying an additional 1,313,036 shares during the period. Woodline Partners LP grew its holdings in shares of BridgeBio Pharma by 132.9% during the fourth quarter. Woodline Partners LP now owns 2,211,521 shares of the company's stock valued at $60,684,000 after buying an additional 1,261,772 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its position in shares of BridgeBio Pharma by 4,544.6% in the 1st quarter. Assenagon Asset Management S.A. now owns 1,120,933 shares of the company's stock valued at $38,751,000 after acquiring an additional 1,096,799 shares during the period. Hedge funds and other institutional investors own 99.85% of the company's stock.
About BridgeBio Pharma
(
Get Free Report)
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BridgeBio Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BridgeBio Pharma wasn't on the list.
While BridgeBio Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
